Instrument number PB 130 of 2008
Amendment special arrangements under subsection 100(1) of the National Health Act 1953
I, DIANA MACDONELL, Acting Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under subsection 100(1) of the National Health Act 1953.
Dated 3rd DECEMBER 2008
DIANA MACDONELL
Acting Assistant Secretary
Pharmaceutical Evaluation Branch
Department of Health and Ageing
Amendment Special Arrangements — Chemotherapy Pharmaceuticals Access Program
1 Commencement
This instrument commences on 1 January 2009.
2 Amendment of PB 121 of 2008
Schedule 1 amends PB 121 of 2008.
Schedule 1 Amendments
[1] Schedule 2, item dealing with Carboplatin in the form Solution for
I.V. injection 450 mg in 45 mL
in the column headed “Brand” insert in alphabetical order:
Baxter Carboplatin
[2] Schedule 2, item dealing with Paclitaxel in the forms Solution concentrate for I.V. infusion 30 mg in 5 mL vial, Solution concentrate for I.V. infusion 100 mg in 16.7 mL vial, Solution concentrate for I.V. infusion 150 mg in 25 mL vial and Solution concentrate for I.V. infusion 300 mg in 50 mL vial
omit from “Column 2” the word:
vial
[3] Schedule 2, item dealing with Paclitaxel in the forms Solution concentrate for I.V. infusion 30 mg in 5 mL, Solution concentrate for I.V. infusion 100 mg in 16.7 mL and Solution concentrate for I.V. infusion 300 mg in 50 mL
in the column headed “Brand” insert in alphabetical order:
Baxter Paclitaxel